British Patient Capital โ Full Portfolio
11 tracked investments ยท listed companies and verified rows first
Pragmatic is a European semiconductor company developing clean chips designed to reduce carbon emissions and waste compared to silicon alternatives.
CleantechDeep TechHardwareSemiconductorsCambridge, GB
Co-investorsIn-Q-TelProsperity7 VenturesARMCambridge Innovation CapitalCatalystNorth East Development Capital Fund+4 more
TOM VIP้ฎ็ฎฑ provides a paid email service for individuals and businesses, offering SSL-encrypted email, a dedicated VIP channel, and mobile email management integrated with WeChat.
Enterprise SoftwareSaaS
Co-investorsCathay Capital
Accurx builds a communication platform that connects patients with healthcare professionals, supporting tasks like appointment booking, patient contact, referrals, video consultations, and health surveys.
Digital HealthHealthtechSaaSLondon, GB
Jacob Haddad(CEO)inLaurence Bargery(Founding CTO)in
Co-investorsEntrepreneur FirstMoonfire VenturesTranspose Platform ManagementAtomicoLakestar
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsSV Health InvestorsDCVC BioRA CapitalDementia Discovery FundLightstone VenturesOno Venture Investment, Inc.+2 more
Cambridge GaN Devices is a fabless semiconductor company that develops energy-efficient GaN-based power devices for sustainable electronics.
CleantechDeep TechEnergyHardwareSemiconductorsCambridge, GB
Fabio Necco(CEO)in
Co-investorsCambridge Innovation CapitalEMV CapitalIQ CapitalMartlet Capital
CloudNC develops CAM Assist, software for machine shops that automates programming, quoting, and tool selection to reduce manual work and increase productivity.
Advanced ManufacturingAI & Machine LearningEnterprise SoftwareSaaSLondon, GB
Theo Saville(Founder)inChris Emery(CTO)in
Co-investorsAdelineBackedBootstrap EuropeEntrepreneur FirstEpisode1GRIDS Capital+7 more
Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
BiotechDigital HealthHealthtechMedical DevicesOxford, GB
Peter Joyce(Co-founder)inTom McCarthy(Co-founder)in
Co-investorsAndera PartnersCanaan PartnersOxford Science EnterprisesPfizer Venture InvestmentsEarlybird Venture CapitalPfizer Ventures
Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsM VenturesOxford Science EnterprisesPfizer Venture InvestmentsJJDCPfizer Ventures
Perspectum develops digital medical technology and diagnostics using multiparametric MRI to assess and diagnose chronic systemic diseases including liver disease, long COVID, diabetes, and cancer for clinicians and patients.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesOxford, GB
Rajarshi Banerjee(CEO)in
Co-investorsBlue Venture FundsHealthQuest Capital
Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.
BiotechDigital HealthHealthtechMedical Devices
Moin Saleem(Co-founder & Chief Scientific Advisor)in
Co-investorsSofinnova PartnersForbionGilde Healthcare
Rows marked โSEC filingโ are inferred from directors named on the company's SEC Form D โ public regulatory data, not a portfolio list published by the firm.